Peter Nash drpnash
2 years 4 months ago
LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL
3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024
Peter Nash drpnash
2 years 4 months ago
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024
Peter Nash drpnash
2 years 4 months ago
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024
Aurelie Najm AurelieRheumo
2 years 4 months ago
And were are on folks!! 🎙️
Delighted to join @RheumNow faculty again this year
I will be covering RA and PsA topics during #EULAR2024
Don’t miss our Daily recaps live 6pm
Oh and if you see me around, come and say Hi! https://t.co/TrQ9b3WeSy
Peter Nash drpnash
2 years 4 months ago
Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024
Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab. Despite this, some patients remain refractory to these effective therapies.
Dr. John Cush RheumNow
2 years 4 months ago
Australian studyshows knee OA pts unconsciously believe that activity may be dangerous to their condition, despite medical advice telling them otherwise. 69% of people with knee pain had stronger implicit (unconscious) beliefs that exercise was dangerous https://t.co/iytfpcGvD8 https://t.co/N183ffYfPP
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 4 months ago
#EULAR2024 Opening Ceremony. @DanielAletaha highlighted values of @eular strategies that have been achieved:
Patient centredness ✔️
Innovation ✔️ - RheumaFacts, ENTRI, Exams
Inclusivity ✔️
To strive on 3 other values by next year under President-Elect @XBaraliakos @RheumNow https://t.co/wDR2vtv3I2
Mrinalini Dey DrMiniDey
2 years 4 months ago
đź“„ #EULARAdvocacy Chair @carmona_loreto discusses the @eular_org manifesto at the #EULAR2024 opening ceremony
đź”—You can read the full manifesto and find out more here: https://t.co/6CZuSYpiLl
@RheumNow https://t.co/DYcU9I6rmR
Aurelie Najm AurelieRheumo
2 years 4 months ago
« We must work together to achieve a future where RMDs are no longer an invisible problem »
Wise words from @carmona_loreto during Opening Plenary session #EULAR2024
@RheumNow
TheDaoIndex KDAO2011
2 years 4 months ago
#AB1039 Spanish study 76 LN patients postrenal transplant: 77% females, HTN (68%), LN class IV (42%), mean age 55. Graft loss in 35.5% b/c of acute rjx (22%), chronic rjx (22%), acute w/chronic rjx (22%), graft thrombosis 14.8%, recur LN (11%) #EULAR24 @rheumnow https://t.co/d82i0Z7LUB
Dr. John Cush RheumNow
2 years 4 months ago
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty
On the first day of EULAR 2024, I am debating Janet Pope. To make it more challenging, it’s about JAK inhibitor safety, and I have been allocated to argue against the regulatory safety warning and the randomised controlled trial that supports it. It’s a challenge, but one that has really given me an opportunity to reflect more broadly.
Dr. John Cush RheumNow
2 years 4 months ago
Final countdown to #EULAR2024 and we'll be there. We'll be sharing recaps, videos, and more. Are you ready for it?! https://t.co/BSrRATfxwt
Dr. John Cush RheumNow
2 years 4 months ago
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
https://t.co/tmCra58mYf https://t.co/KbMIDipvpI
